Justin F. Klamerus named EVP, chief medical officer at McLaren Health Care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Justin F. Klamerus was named executive vice president and chief medical officer at McLaren Health Care. 

He will assume the position previously held by Michael McKenna, McLaren Health Care’s first CMO, who died in May 2022.

Klamerus has served as president of Karmanos Cancer Hospital and Network, a subsidiary of McLaren Health Care, since January 2017.

Klamerus’ history with McLaren began in 2009. He served as the program director of cancer services at McLaren Northern Michigan in Petoskey, MI, before becoming president of the McLaren Cancer Institute. In 2014, when McLaren acquired the Karmanos Cancer Institute, he assumed the role of executive vice president and chief quality officer at Karmanos. He was then named president of the organization.

While at Karmanos, Klamerus oversaw the expansion of the Karmanos Cancer Network and led business and clinical partnerships with community physicians, academic faculty, and graduate medical education partners.

In 2020, Klamerus was appointed to the Public Health Advisory Commission by Michigan Governor Gretchen Whitmer.

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login